Trials / Completed
CompletedNCT06862531
A Single-center, Interventional Diagnostic Study With Minimal Risks and Constraints, Aimed at Longitudinally Evaluating Serum Antibody Levels in Patients With COVID-19 According to the Severity of Their Symptoms.
COVERT : A Single-center, Interventional Diagnostic Study With Minimal Risks and Constraints, Aimed at Longitudinally Evaluating Serum Antibody Levels in Patients With COVID-19 According to the Severity of Their Symptoms.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Bioaster · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The COVERT protocol was designed to assess, through a longitudinal analysis, the level of antibodies present in the serum of patients with COVID-19, the duration and the persistence of the humoral response in correlation with the severity of the disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | blood sample | A sample of blood (1mL) was taken |
Timeline
- Start date
- 2020-09-25
- Primary completion
- 2020-11-17
- Completion
- 2020-11-17
- First posted
- 2025-03-06
- Last updated
- 2025-03-06
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT06862531. Inclusion in this directory is not an endorsement.